The launch into the USA market has some growth potential with...

The launch into the USA market has some growth potential with Stirling being hopeful of being able to have product on the market there in time for the North American influenza season and the anticipated high rate of swine flu infection.
The news last night stated..."According to reports from the USA Centers for Disease Control and Prevention (CDC), 40% of Americans could get the swine flu over the next couple of years and several hundred thousand could die should the vaccine campaign prove to be of no avail. In fact the
proposed vaccine, which is unproven against swine flu as there has not been the opportunity to properly trial it against the strain, will not be available in the USA for at least several months".
The apparent success of ImmunoXel in the Ukraine with only one reported case of swine flu in that country is an interesting marketing strategy which Stirling has not used very effectively to date to stimulate growth in sales to date but if they get their marketing right, has a possible large market..."it has been observed to be effective in the prevention of and treatment of seasonal flu in the Ukraine
over the past approximate 15 years where it is sold through pharmacy outlets".
15 years of success is better than clinical trials but the clinical trials is where the retailers will take note and the cash flows begin in earnest.